A Study To Identify Biomarkers In The Blood, Saliva Or Tissue For Oropharyngeal Squamous Cell Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 19-006036
NCT ID: NCT06356272
Sponsor Protocol Number: 19-006036
About this study
The purpose of this study is to identify a biomarker (or biomarkers) that is present when disease is present (i.e., at diagnosis or recurrence) and not present when disease is absent (i.e., after treatment, in HPV negative patients or in normal controls).
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Age ≥ 18 years old.
- Able to provide written consent.
- Patient has given permission to give his/her tumor/tissue/blood/saliva sample for research testing.
- Clinical diagnosis of oropharyngeal squamous cell carcinoma.
- Ability to complete questionnaire(s) by themselves or with assistance.
- Willingness to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
Exclusion Criteria:
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm. Patients enrolled in DART are eligible.
- Other active malignancy ≤ 5 years prior to registration.
- Exceptions: Non-melanotic skin cancer, non-metastatic thyroid cancer, non-metastatic prostate cancer, carcinoma-in-situ of the cervix.
- Note: If there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Kathryn Van Abel, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available